Cancer Immunotherapy Market
Report ID: SQMIG35H2344
Report ID: SQMIG35H2344
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2344 |
Region:
Global |
Published Date: December, 2025
Pages:
197
|Tables:
120
|Figures:
69
Global Cancer Immunotherapy Market size was valued at USD 135.93 Billion in 2024 and is poised to grow from USD 147.35 Billion in 2025 to USD 280.92 Billion by 2033, growing at a CAGR of 8.4% during the forecast period (2026–2033).
The Cancer Immunotherapy Market is experiencing robust growth due to rising incidence of cancer, increasing demand for targeted drugs, and technology advancement in immuno-oncology. Of the key drivers is the enhanced application of immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 inhibitors, that have proved effective over traditional treatments. Also, the development of personalized medicine and CAR-T cell therapies is transforming treatment paradigms with enhanced and sustainable outcomes for some cancer indications.
Continued R&D spending and strong pipelines of immunotherapies additionally reinforce speeding up innovation within this space, particularly for challenging-to-treat cancers like melanoma, lung, and hematologic malignancies.The favorable regulatory environment and increased public-private partnerships to speed up approvals of new immunotherapies are another key driver. Regulatory agencies such as the FDA and EMA have prioritized cancer immunotherapy drugs using expedited approval procedures, which enable prompt access by patients to innovative treatments. Higher awareness and early screening programs combined with a rapidly growing population aged in cancer-prone years are spurring demand across the globe. Apart from this, increasing adoption of biomarkers and companion diagnostics is assisting in identifying patient subsets likely to derive benefit, hence improving clinical effectiveness as well as cost-effectiveness.
As for restraints, the cancer immunotherapy market is faced with high treatment costs as well as limited access in low- and middle-income countries. The complexity involved in the production of cell-based products such as CAR-T renders them costly and logistically demanding, hence restraining adoption among a large population. Additionally, immune toxicities, including autoimmune responses and cytokine storms, are severe clinical risks, requiring vigilant patient monitoring. Furthermore, certain patients exhibit primary or acquired resistance to immunotherapies, limiting the curability of treatment and requiring combination therapies and innovative mechanisms of action. Despite these constraints, ongoing technological advancements and expanding clinical uses remain to create hope in the realm of cancer immunotherapy.
Artificial Intelligence (AI) is transforming the cancer immunotherapy market by enhancing patient selection, optimizing treatment strategies, and amplifying clinical outcomes. AI algorithms have the ability to analyze huge volumes of data—genomic, proteomic, and clinical data—to reveal patterns and predict patient outcomes to immunotherapies. This enables oncologists to tailor treatment for each patient, which increases the likelihood of success and reduces unwarranted exposure to ineffective treatments. In addition, AI facilitates the discovery of novel biomarkers and therapeutic targets, accelerate the development of next-generation immunotherapies. Among the latest developments that highlight AI's impact is the creation of SCORPIO, an artificial intelligence platform developed by Mount Sinai and Memorial Sloan Kettering Cancer Center researchers. SCORPIO relies on routinely available blood tests and clinical data to predict outcomes with immune checkpoint therapies, demonstrating superior efficacy to current FDA approved biomarkers including tumor mutational burden and PD-L1 immunostaining. With low-cost, routinely available tests, SCORPIO presents access to personalized cancer care that is more effective, cost-lower, and equitable for patients globally.
Market snapshot - 2026-2033
Global Market Size
USD 136.4 billion
Largest Segment
Monoclonal Antibodies
Fastest Growth
Monoclonal Antibodies
Growth Rate
9.0% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Cancer Immunotherapy Market is segmented by Type, Application, Route of Administration, End User and region. Based on Type, the market is segmented into Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma and Others. Based on Route of Administration, the market is segmented into Intravenous (IV), Intramuscular and Oral. Based on End User, the market is segmented into Hospitals & Clinics, Cancer Research Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Checkpoint inhibitors hold an outstanding market share in cancer immunotherapies because of their efficacy in a number of cancers and the support of the government. PD-1 inhibitors pembrolizumab and nivolumab, represent the largest holding of the market, commanding a 73.3% market share by 2023, due in large part to their work in recent cancer therapies for lung cancer (which commands a 25.41% market share in 2023 alone). Governmental support have also assisted this growth. For example, in July 2023, the U.S. Cancer Research Institute funded roughly USD 28 million for continued support of research in immunotherapy and checkpoint inhibitors. Addition, the European Commission marketing authorization for pembrolizumab plus chemotherapy for advanced endometrial carcinoma is yet another signal of increased regulatory support for these treatments. Together, these various factors work to secure a unique global leadership position for checkpoint inhibitors.
Monoclonal antibodies (mAbs) are the fastest-growing segment of cancer immunotherapy. Their specificity in targeting cancer cells with minimal damage to normal tissues has led to widespread applications. There is government support evidence, such as Amgen's bispecific antibody Imdelltra for the treatment of small cell lung cancer, which was approved by the U.S. FDA and demonstrated a 40% reduction in risk of death. The achievements underscore the forefront position of mAbs in enhancing cancer treatment globally.
Lung cancer is the major cancer in terms of market share for cancer immunotherapy due to its high incidence and mortality rates around the world.In 2022, lung cancer had approximately 2.5 million new cases (12.4% of all cancers) and 1.8 million deaths (18.7% of cancer deaths) around the world. It's undeniable that tobacco smoking is the main risk factor equating to roughly 85% of lung cancer patients, and both include second-hand exposure, various occupational exposures, and air pollution. All these, as well as late diagnoses, reflect the necessity for effective immunotherapy treatments in managing lung cancer.
The fastest-growing segment of the cancer immunotherapy market is melanoma. Government-funded initiatives, such as the NHS Cancer Vaccine Launch Pad in the UK, are spearheading access to personalized vaccines like iSCIB1+ for advanced-stage melanoma patients. In addition, the FDA's 2024 approval of the first T-cell therapy of tumor origin, lifileucel (Amtagvi), is a milestone advancement in treating unresectable or metastatic melanoma.
To get detailed segments analysis, Request a Free Sample Report
North America holds the largest share of the global cancer immunotherapy market, accounting for approximately 44.4% in 2023. This dominance is attributed to robust healthcare infrastructure, significant research funding, and favorable regulatory environments.
U.S. Cancer Immunotherapy Market
The U.S. leads the North American market due to advanced R&D, regulatory support, and biotech hubs. Companies like Merck (Keytruda) and Bristol-Myers Squibb (Opdivo) dominate. In 2023, Merck secured FDA approval for Keytruda in early-stage NSCLC, expanding patient access and strengthening market leadership.
Canada Cancer Immunotherapy Market
Canada benefits from strong government healthcare funding and clinical trial networks. Companies such as Pfizer are prominent here. Recently, Pfizer’s cancer vaccine research received CAD 20 million in Canadian government grants in 2024, accelerating immunotherapy development and increasing regional market penetration.
The Asia-Pacific region is experiencing the most rapid growth in the cancer immunotherapy sector. Countries like China, Japan, and India are at the forefront, driven by increasing cancer incidences and expanding healthcare investments. Government initiatives, such as China's approval of durvalumab (Imfinzi) for biliary tract cancer, exemplify the region's commitment to enhancing cancer treatment options. Additionally, the establishment of manufacturing facilities by global leaders in these countries is contributing to cancer immunotherapy market expansion.
China Cancer Immunotherapy Market
China is #1 because they are in many ways worlds ahead of the pack due to with the massive diversity of a patient population and a government that truly understands the need for biopharma innovation (ie. growing and diversifying their economy at the same time they treat).
Japan Cancer Immunotherapy Market
Japan dominates with advanced healthcare infrastructure and strong government backing for immunotherapy. Takeda's recent collaboration with Japan’s AMED focuses on developing next-gen immune checkpoint inhibitors, leveraging government grants to accelerate clinical trials and regulatory approvals.
South Korea Cancer Immunotherapy Market
South Korea leads in biopharmaceutical manufacturing with strong government R&D funding. Samsung Biologics recently expanded its cell therapy manufacturing facility, bolstered by government support to promote Korea as a global immunotherapy production hub.
Europe has maintained a great cancer immunotherapy market share, led by Germany, France, and the UK, which have been quick to adopt these therapies. Europe benefits from established healthcare systems and large-scale research funding. For instance, the European Commission's approval of pembrolizumab in combination with chemotherapy for advanced endometrial carcinoma demonstrates the region's forward-thinking attitude towards the integration of new treatments.
Germany Cancer Immunotherapy Market
BASF SE is in the lead due to strong research and development capabilities and its competence in the chemical area that supports new drug formulations. The emphasis on funding from the government has recently speeded their immunotherapy projects and advocated for advanced antibody-drug conjugates to use for resistant cancers.
France Cancer Immunotherapy Market
France's dominant Sanofi is a key player in cancer immunotherapy, with government-funded programs that support cancer immunotherapy and ultimately clinical trials. The collaborative work between Sanofi and INSERM researching to make novel monoclonal antibodies is a good.
UK Cancer Immunotherapy Market
GlaxoSmithKline (GSK) is the big player through its broad immuno-oncology pipeline and partnerships, such as the iSCIB1+ melanoma vaccine clinical trial backed by the NHS. The Cancer Vaccine Launch Pad is another UK government-supported operation intended to support rapid clinical uptake.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Growing Cancer Incidences:
Technological Development in Cancer Diagnosis and Treatment:
Expensive Treatment:
Growing Prevalence of Immune-Related Cases:
Request Free Customization of this report to help us to meet your business objectives.
The competitive environment surrounding cancer immunotherapy is rife with partnerships, research and R&D funding, and the government has become an innovation accelerator. The bigger market players (i.e., Merck, Bristol-Myers Squibb, Novartis) are branching out into new discovery pipelines through public-private partnerships. In 2024, the Biomedical Advanced Research and Development Authority (BARDA) provided funding of approximately USD 50 million as part of the advanced immunotherapies initiative. Multiple governments around the world including Japan MINERVA (Japan Agency for Medical Research and Development) are also funding clinical trials with advanced next generation therapies, bispecific antibodies and personalized vaccines. We are also witnessing international regulatory harmonization in the international regulatory harmonization through the International Council for Harmonisation (ICH) leading to enhanced timelines on drug approval processes alongside competitive opportunities in an international environment.
Personalized immunotherapy is becoming popular as countries globally provide funding for precision medicine initiatives. The United States National Cancer Institute provided more than USD 45 million in 2024 for immunotherapy research in the area of genomics that has allowed personalized treatments to improve treatment effectiveness and reduce toxicity. The advancements needed to create personalized immunotherapy treatment options will improve care for patients internationally.
Governments are supporting clinical trials, which is accelerating the uptake of immunotherapy. The Japanese AMED provided funding for numerous large clinical trials in 2023 and is quickly directing funding towards bispecific antibodies that can rapidly advance development and regulatory approvals. The ultimate development of bispecific antibodies for immunotherapies will improve treatment options within a specific market, but also improve market expansion throughout the Asia-Pacific region.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected using Primary Exploratory Research backed by robust Secondary Desk research.
According to global market analysis, the cancer immunotherapy market continues to be driven by the efficacy of checkpoint inhibitors in a variety of cancer types and increasing government investment in immunotherapy research and development, while the rising use of personalized medicine as a treatment option is driving research and development in the field. High treatment costs and immune-related adverse events are consistent challenges that are likely to limit acceptance across the board. Both North America and Asia-Pacific are the two leading regions of opportunity, although for distinctly different reasons. North America is a leader in this area of Economic opportunity because of its world-class infrastructure, investment capabilities, and regulations. Looking to Asia-Pacific, the region is growing rapidly due to the higher-than-average cancer incidence rate and improving access to health care coverage that is further supplemented by government approvals of various innovative therapies. The unique collaborations, government-backed research opportunities, and global regulatory convergence could lead the market to unprecedented levels of growth and competition.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 135.93 Billion |
| Market size value in 2033 | USD 280.92 Billion |
| Growth Rate | 8.4% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Cancer Immunotherapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Immunotherapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Immunotherapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cancer Immunotherapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Personalized immunotherapy is becoming popular as countries globally provide funding for precision medicine initiatives. The United States National Cancer Institute provided more than USD 45 million in 2024 for immunotherapy research in the area of genomics that has allowed personalized treatments to improve treatment effectiveness and reduce toxicity. The advancements needed to create personalized immunotherapy treatment options will improve care for patients internationally.
The market for cancer immunotherapy is projected to have a compound annual growth rate of 9.0% from 2025 to 2032, with the growth drivers including the increase in cancer incidence, technology improvements and growing demand for targeted immuno-oncology therapies.
The main types are Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors and Immunomodulators. Each has a different mechanism of enhancing the immune system's capabilities to recognize and destroy cancer cells.
Monoclonal antibodies target cancer cells with higher specificity while largely sparing normal tissues. Monoclonal antibodies are the fastest growing segment of cancer immunotherapy due to their specificity and the advancement of breakthroughs spearheaded by the government, such as Amgen's Imdelltra.
Cancer vaccines provide the means to stimulate the immune system to recognize and attack cancer cells. Many initiatives are backed to support cancer vaccine developments, like the NHS Cancer Vaccine Launch Pad in the UK, and highlight the emergence of cancer vaccines as part of advanced-stage cancer treatments - melanoma in particular.
Immunotherapy is a conventional treatment across all lung, breast, colorectal, melanoma, prostate, and hematologic cancers, especially when conventional treatments show less effect or have limited efficacy for patients.
The main end-users are Hospitals & Clinics, Cancer Research Centers, and Others. While hospitals and research institutions play the largest role in providing treatment, both groups play a vital role in advancing innovation in cancer therapy with immunotherapy.
Cancer research centers are advancing beyond shared intellectual property, through clinical trials, R&D and strategies for collaboration, all supported by public-private funding sources. Their research and development encourages next generation therapies, such as CAR-T, and innovative personalized cancer vaccines.
Typically, governments are able to hasten drug approvals through regulatory agencies like the FDA and EMA and their requests for immunotherapies and funding for clinical trials, which improves access and accelerates the market by eliminating barriers through the use of regulations and funding grants.
North America is a leader in this sector as it is home to significant healthcare infrastructure, high levels of investment in R&D, and incentives and support from regulators. The United States and its numerous biotech hubs and approvals from the FDA, especially with Keytruda and its recent expansion, is a major contributing factor to the region’s dominance.
Even though immunotherapy offers significant market growth potential, high costs for therapies to patients, particularly with complicated CAR-T medications, and limited access for low income areas, will slow universal acceptance and slow the growth of the global immunotherapy market.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
